Huimin Wu
Internal Medicine · Washington, DCNPI 1083902506
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,553 of the $2,010 with a category attached, or 77.3%. 17 manufacturers reported payments, led by AstraZeneca at 28.3% of the total. Reporting peaked in 2019 at $665 and has fallen 62.6% since, to $249 in 2025.
Across 59 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$570
- Astrazeneca UK Limited$196
- Inogen, Inc.$175
- GSK$167
- Boehringer Ingelheim$141
- Actelion Pharmaceuticals US, Inc.$119
- plus $642 from 11 others
Across 11 payments — averaging $8112.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$56K
- Chiesi USA, Inc.$33K
What the payments were for
- Travel & lodging$45122%
- Food & beverage$1,55377%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $570 |
| Astrazeneca UK Limited | 1 | $196 |
| Inogen, Inc. | 14 | $175 |
| GSK | 9 | $167 |
| Boehringer Ingelheim | 7 | $141 |
| Actelion Pharmaceuticals US, Inc. | 1 | $119 |
| United Therapeutics Corporation | 1 | $119 |
| Insmed, Inc. | 1 | $108 |
| Viatris Specialty LLC | 2 | $104 |
| Pulmonx Corporation | 2 | $88 |
| Sanofi | 1 | $53 |
| Bayer | 3 | $49 |
| Vifor Pharma, Inc. | 2 | $34 |
| Portola Pharmaceuticals, LLC | 1 | $34 |
| Novartis | 1 | $21 |
| Edwards Lifesciences | 1 | $18 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,010 in reported general payments places this provider in the 85th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $122,910 |
| Spiriva RespimatTiotropium Bromide | 50 | $38,170 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $15,092 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $14,260 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,311 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,096 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $3,518 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,225 |
| Roflumilast | 12 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $167 | $147,313137 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $141 | $52,42978 claims |
| AstraZenecaSymbicort | $570 | $9,09627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.